What are the treatment options for KRAS G13D colorectal cancer?
KRAS G13D is a RAS-mutant colorectal cancer, so anti-EGFR antibodies such as cetuximab and panitumumab are not standard therapy. Treatment centers on chemotherapy backbones with an antiangiogenic agent, with immunotherapy if the tumor is MSI-high, and trials of RAS-directed agents are an increasingly relevant option to screen for.
Why G13D changes the anti-EGFR question
Extended RAS testing exists mainly to decide whether cetuximab or panitumumab should be used. Tumors with RAS mutations, G13D included, are generally not treated with those antibodies outside a study, because the pathway is activated downstream of the receptor being blocked.
G13D has a long research history of retrospective signals suggesting it might behave differently from other codon 12 and 13 mutations, but prospective data has not established it as an exception in routine practice. Anyone quoting older subgroup analyses should be asked what prospective evidence supports them.
What the plan usually looks like
Standard systemic therapy rests on fluoropyrimidine-based regimens, typically FOLFOX or FOLFIRI, often combined with bevacizumab or another antiangiogenic agent, with sequencing decided by prior treatment, tolerance, and goals. Later lines include regorafenib and trifluridine/tipiracil combinations.
- Confirm MSI/dMMR status: if MSI-high, immunotherapy changes the entire plan
- Confirm BRAF V600E status, which carries its own targeted combination
- Check HER2 amplification, which opens HER2-directed options in colorectal cancer
- Check tumor sidedness, which influences regimen selection
RAS-directed development matters here
RAS is no longer undruggable. G12C inhibitors are approved in other settings, and broader RAS inhibitors are advancing quickly. Daraxonrasib, a multi-selective RAS(ON) inhibitor, was approved by the FDA in August 2026 for metastatic pancreatic adenocarcinoma after at least one prior systemic therapy, based on the RASolute 302 trial, which is not a colorectal indication but signals how fast this class is moving.
For a non-G12C RAS mutation such as G13D, screening open trials of pan-RAS and combination approaches is a practical part of planning rather than a last resort.
Related questions
Is there an approved targeted drug for KRAS G13D?
No targeted agent is approved specifically for G13D. Approved KRAS-directed drugs target G12C, and broader RAS inhibitors are in development or approved in other tumor types.
Could cetuximab ever be used with G13D?
Only in a study or an unusual, individually justified situation. Standard practice excludes anti-EGFR antibodies for RAS-mutant colorectal cancer.
What testing should I make sure was done?
Extended RAS, BRAF, MSI or mismatch repair, HER2, and ideally a broad panel with fusion detection. Gaps in that set are common and change what is available to you.
Reviewed 2026-09-22 by Kim Lockheimer, PhD, DFM.